Buscar resultados de ensayos clínicos

Patrocinado por

Abnormalities, Multiple - 435 Studies Found

Estado Estudiar
Completed Nombre del estudio: Development of a Blood Test for Marfan Syndrome
Condición:
  • Marfan Syndrome
  • Marfan Related Disorders
  • Control Subjects<
    Fecha: 2014-05-23
Completed Nombre del estudio: Down Syndrome Biomarker Initiative (DSBI)
Condición:
  • Down Syndrome
  • Alzheimer's Disease

Fecha: 2014-05-16
Completed Nombre del estudio: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Condición:
  • Alagille Syndrome
  • Progressive Familial Intrahepatic Cholestasis

Fecha: 2014-05-01
Completed Nombre del estudio: Non Invasive Prenatal Testing of Down Syndrome
Condición: Down Syndrome
Fecha: 2014-04-02
Intervenciones:
  • Procedure: Non Invasive Prenatal Testing
  • P
Active, not recruiting Nombre del estudio: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Condición: Alagille Syndrome
Fecha: 2014-04-16
Intervenciones: Drug: LUM001 Administered orally daily
Active, not recruiting Nombre del estudio: Thoracic Aortic Dilatation Syndromes
Condición:
  • Thoracic Aorta Dilatation
  • Marfan Syndrome

Fecha: 2014-04-09
Completed Nombre del estudio: Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
Condición:
  • Microdeletion Syndromes
  • Trisomy 21
  • Trisomy 18
  • Fecha: 2014-04-08
Active, not recruiting Nombre del estudio: Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
Condición: Basal Cell Nevus Syndrome
Fecha: 2014-02-28
Intervenciones: Drug: BMS-833923 BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
Active, not recruiting Nombre del estudio: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
Condición: Down Syndrome
Fecha: 2014-03-19
Intervenciones:
  • Drug: E2020-Donepezil hydrochloride

Active, not recruiting Nombre del estudio: Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
Condición: 22q11 Deletion Syndrome
Fecha: 2014-02-17
Intervenciones:
  • Dietary Supplement: omega-3 PUFAs

<<< Previous | Next >>>